p53 protein expression in human breast cancer: An immunohistochemical study including correlation with steroid receptor status, proliferation indices, collages type IV, laminin, c-erbB-2 oncoprotein and Cathepsin D

Breast

Volumn 7, Issue 1, 1998, Pages 42-48

  Ioachim, E ^a   Skopelitou, A ^a   Kamina, S ^a   Nonni, A ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; COLLAGEN TYPE 4; CYCLINE; KI 67 ANTIGEN; LAMININ; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P53; STEROID RECEPTOR;

ADULT; ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0031895119     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(98)90051-0     Document Type: Article

References (50)

1. Mercer W E, Avignolo C, Baserga R. Role of the p53 protein in cell proliferation as studied by micro injection of monoclonal antibodies. Mol Cell Biol 1984; 4: 276-282.
2. Reich N C, Levine A J. Growth regulation of a cellular tumour antigen p53, in nontransformed cells. Nature 1984; 308: 199-201.
3. Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K. Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. Requirement for cell cycle progression. Oncogene 1990; 5: 1701-1706.
4. Finlay C A, Hinds P W, Levine A J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
5. Finlay C A, Hinds P W, Tan T H, Eliyahu D, Oren M, Levine J. Activating mutations for transformation by p53 produce a gene product that forms as hsc-70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531-539.
6. Iggo R, Gather K, Bartek J, Lane D, Harris A L. Increased expression of mutant form of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
7. Nigro J M, Baker S J, Preisinger A C et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
8. Porter P, Gown A, Kramp S, Coltrera M. Widespread p53 overexpression in human malignant tumours. Am J Pathol 1992; 140: 145-153.
9. Cattoretti G, Rilke R, Andreola S, D'Amato S, Dellia D. p53 expression in breast cancer. Int J Cancer 1988; 41 178-183.
10. Caleffi M, Teague M W, Jensen R A, Vnencak-Jones C L, Dupont W D, Pari F F. p53 gene mutations and steroid receptor status in breast cancer. Cancer 1994; 73: 2147-2156.
11. Bartek J, Iggo R, Gannon J, Lane D P. Genetic and immunohistochemical analysis of mutant p53 in human cancer cell lines. Oncogene 1990; 5: 893-899.
12. Thompson A M, Steel C M, Chetty U et al. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990; 61: 74-78.
13. Chang K, Ding I, Kern F G, Willingham M C. Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. J Histochem Cytochem 1991; 39: 1281-1287.
14. Davidoff A M, Humphrey P A, Iglehart J D, Marks J R. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88: 5006-5010.
15. Varley J M, Brammar W J, Lane D P, Swallow J E, Dolan C, Walker R A. Loss of chromosome 17p 13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991; 6: 413-421.
16. Davidoff A M, Kerns B M, Iglehart J D, Marks J R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991; 51: 2605-2610.
17. Walker R A, Dearing S J, Lane D P, Varley J M. Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 1991; 165: 203-211.
18. Davidoff A M, Herndon J E, Glover N S et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 259-264.
19. Bloom H J G, Richardson W W. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-377.
20. Elston C W. Grading of invasive carcinoma of the breast. In: Page D L, Anderson T, eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987: 300-311.
21. Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long follow-up. Histopathology 1991; 19: 403-410.
22. Hsu S M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Hisotchem Cytochem 1981; 29: 577-580.
23. Hall P A, Levison D A, Woods A L et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285-294.
24. Ostrowski J L, Sawan A, Henry L et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164: 75-81.
25. Bosari S, Lee A K C, Viale G, Heatley G J, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv A Pathol Anat Histopathol 1992; 421: 291-295.
26. Barbareschi M, Leonardi E, Mauri F, Serio G, Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98 408-418.
27. Barnes D M, Dublin E A, Fisher C J, Levison D A, Millis R R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum pathol 1993; 24: 469-476.
28. Gerdes J, Lelle R J, Pickartz H et al. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol 1986; 39: 977-980.
29. Yewdell J W, Cannon J V, Lane D P, Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 1986; 59: 444-452.
30. Barnard N J, Hall P A, Lemonine N R, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 1987; 152: 287-295.
31. Bouzubar N, Walker K J, Griffiths K et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 1989; 59: 943-947.
32. Battersby S, Anderson T J. Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 1990; 21: 781.
33. Shohat O, Greenberg M, Reisman D, Oren M, Roter V. Inhibition of cell growth mediated by plasmids encoding p53 antisense. Oncogene 1987; 1: 277-283.
34. Yonemura Y, Kimura H, Fushida S et al. Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer. 1993; 71: 2448-2453.
35. Leonardi E, Girlando S, Serio G et al. PCNA and Ki-67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol 1992; 45: 416-419.
36. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
37. Tandon A K, Clark G M, Chamness G C, Ullrich A, McGuire W L. HER-2/neu oncogen protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.
38. Walker R A, Gullick W J, Varley J M. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short term prognosis in breast cancer. Br J Cancer 1989; 60: 426-429.
39. Wright C. Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49: 2087-2090.
40. Umekita Y, Takasaki T, Yoshida H. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: an immunohistochemical study. Virchows Arch 1994; 424: 491-494.
41. Poller D N, Roberts E C, Bell J A, Elston C W, Blarney R W, Ellis I O. P53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993; 24: 463-468.
42. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi O P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11: 36-43.
43. Eng Tan P, Benz C C, Dollbaum C et al. Prognostic value of Cathepsin D expression in breast cancer: Immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 1994; 5: 329-336.
44. Domagala W, Striker G, Szadowska A, Dukowicz A, Weber K, Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry: no correlation with survival at 5 years. Am J Pathol 1992; 141: 1003-1012.
45. Henry J A, McCarthy A L, Angus B. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. Cancer 1990; 65: 265-271.
46. Martinez-Hernandez A, Amenta P S. The basement membrane in pathology. Lab Invest 1983; 48: 656-677.
47. Liotta L A, Rao C N, Barsky S H. Tumour invasion and the extracellular matrix. Lab Invest 1983; 49: 636-650.
48. Barsky S H, Togo S, Garbisa S, Liotta L A. Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet 1983; i: 296-297.
49. Albrechtsen R, Nielsen M, Wewer U, Engvall E, Ruoslahti E. Basement membrane changes in breast cancer detected by immunohistochemical staining for laminin. Cancer Res 1981; 41: 5076-5081.
50. Gusterson B A, Warburton M J, Mitchell D, Ellison M, Neville A M, Rudland P S. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast disease. Cancer Res 1982; 42: 4763-4770.